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Abstract
Background: Resistance to anoikis, apoptosis triggered by a loss of cellular adhesion to the underlying extracellular matrix,
is a hallmark of metastatic cancer. Previously we have shown re-establishment of CXCL12 expression in colorectal carcinoma
cells inhibits metastasis by enhancing anoikis sensitivity. The objective of these studies was to define the signaling
mechanisms regulating CXCL12-mediated anoikis.
Methodology/Principal Findings: Adhesion, examined by crystal violet staining, immunofluorescence microscopy, and
immunoblot analysis indicated decreased focal adhesion signaling corresponding with loss of adhesion in cells
constitutively simulated by CXCL12. Loss of adhesion was inhibited by pertussis toxin treatment, indicating CXCL12
regulating anoikis through Gai-protein coupled receptors. Non-adherent HCT116 and HT29 colorectal carcinoma cells
expressing CXCL12 exhibited enhanced anoikis sensitivity by propidium iodide staining, caspase activity assays, and
immunoblot compared to GFP control cells. CXCL12 producing carcinomas cultured on poly-HEMA displayed heightened
Bim and loss of Mcl-1 and Bcl-2 preceding cytochrome c release, and caspase-9 activation. RNAi knockdown of Bim reversed
anoikis sensitivity of CXCL12-expressing cells and fostered increased soft-agar foci formation and hepatic tumors in an
orthotopic mouse model of metastasis.
Conclusions/Significance: These data indicate CXCL12 provides a barrier to metastasis by increasing anoikis via activation
of a Bim-mediated intrinsic apoptotic pathway. These results underscore the importance of retaining CXCL12 expression to
sensitize colorectal carcinomas to anoikis and minimize tumor progression.
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Introduction
Intestinal epithelial cells migrate along the crypt-villus axis
where their survival is dependent on integrin binding to the
underlying extracellular matrix (ECM). At the villus apex,
epithelial cells are shed into the lumen through loss of ECM
contact and undergo apoptosis, a process coined anoikis [1–5].
Anoikis is not only essential for maintaining normal epithelial
homeostasis but also provides a strong physiological barrier to
cancer progression. Resistance to anoikis is a hallmark of
metastatic carcinomas where cells require survival in an
anchorage-independent environment such as the bloodstream to
seed distant tissues [6]. The cellular and biochemical mechanisms
that regulate how metastatic carcinomas lose responsiveness to
anoikis remain poorly defined.
Anoikis has primarily been described as an intrinsic apoptotic
pathway with cell fate being dictated through mitochondrial outer
membrane permeabilization by Bcl-2 family member proteins [7].
The Bcl-2 family consistsofbothanti-apoptoticand pro-apoptotic
proteins with the balance of these proteins regulating mitochon-
drial cytochrome c release. Anti-apoptotic Bcl-2 proteins such as
Bcl-2, Mcl-1, and Bcl-XL heterodimerize with pro-apoptotic
proteins to inhibit their function [8]. Pro-apoptotic Bcl-2 family
members are further characterized as multi-domain or BH3-only
proteins. Multi-domain pro-apoptotic proteins, Bak and Bax,
contain transmembrane domains that permeabilize the mito-
chondrial outer membrane to release cytochrome c resulting in
activation of caspase-9-dependent apoptosis. BH3-only proteins
such as Bim, Bad, Bmf, Noxa, and Puma sense apoptotic stimuli
and initiate apoptosis through activation of Bak and Bax [8].
Previous studies suggest degradation of Mcl-1 modulates
expression of Bim to repress anoikis [9]. Furthermore, depletion
of Bim enhances anchorage-independent survival in both
transformed and non-transformed cells [9,10]. While the
intracellular mediators regulating detachment-induced cell death
have begun to be elucidated, the key extracellular regulators of
anoikis and the Bcl-2 family of apoptotic effectors have yet to be
fully defined.
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mediators play in regulating anoikis in non-transformed or
transformed epithelia. Oncogenic proteins such as epidermal
growth factor have been shown to induce anoikis resistance
through regulation of Bcl-2 family members [11], while trans-
forming growth factor beta increases anoikis [12]. Our earlier
studies have shown that constitutive expression of the chemokine
CXCL12 induces anoikis in colorectal carcinoma cells [13].
CXCL12 binds to its receptor CXCR4 to mediate cell-type
specific physiological processes including cellular migration,
survival, and apoptosis [14–16]. Notably, CXCL12 and CXCR4
are essential for life as mice deficient in either gene are unable to
survive much past birth [17,18]. CXCL12 was originally described
as a vital chemoattractant for B cells and monocytes [19] but since
has been shown to be involved in cancer progression [20,21].
Carcinomas frequently have elevated CXCR4 expression, which is
a key regulatory element in enabling tumor cell metastasis, a
locomotory event characteristic of migrating immune cells [21].
Concurrently, CXCL12 protein levels are highest in common sites
of metastasis including the liver, bone marrow, and lungs,
suggesting that metastasis is the result of carcinomas indirectly
hijacking chemokine-directed lymphocyte trafficking patterns [20].
Our work has significantly expanded the model that chemokines
strictly regulate leukocyte trafficking and demonstrate that human
colonic epithelial cells expressing both CXCL12 and CXCR4 play
roles in epithelial restitution [22]. Subsequent work from our
laboratory indicates that CXCL12 expression becomes silenced in
both breast and colorectal carcinomas via DNA promoter
hypermethylation and that this epigenetic repression enhances
metastasis [23,24]. In contrast to mammary carcinomas stimulated
with exogenously added CXCL12 [25], we determined that re-
establishment of CXCL12 expression characteristic of the normal
epithelium increases anoikis sensitivity of colorectal carcinoma
cells [13]. Therefore, our working model is that endogenous
expression of CXCL12 by colonic carcinoma cells interrupts
metastasis in part through increased anoikis sensitivity. The
overarching goal of the following studies was to unravel the
biochemical and cellular mechanisms through which CXCL12
induces anoikis in colonic carcinoma cells. For these studies, we
took advantage of our unique colorectal carcinoma cells
engineered to re-express CXCL12. Our data indicate that
constitutive CXCL12 stimulation induces anoikis through an
intrinsic, Bim-dependent apoptotic mechanism. These data
support the model that CXCL12 production by colonic epithelial
cells is a key governor limiting carcinoma progression.
Results
Autocrine CXCL12 reduces cellular adhesion
Initial characterization of HT29 and HCT116 human colorec-
tal carcinoma cells shows expression of both CXCR4 and CXCR7
chemokine receptors with no detectable CXCL12 expression.
MCF7 breast cancer cells, previously shown to express CXCR7
and CXCL12, were used as a positive control (Figure 1A) [23,26].
Our previous studies have shown that autocrine CXCL12 reduces
cellular colorectal carcinoma cell adherence compared to wild-
type colonic carcinoma cells. This decreased ability to adhere to
tissue-culture-treated plastic dishes is shown for HT29 cells
expressing CXCL12, which are increasingly incapable of main-
taining a confluent monolayer compared to control (GFP) cells
(Figure 1B). The loss of adhesion coincides with increased levels of
secreted CXCL12 over that same time span, from not detectable
at day 0 to a maximum after 4-days in culture (data not shown).
Chemokines primarily signal through Gai G-protein coupled
receptors [27]. Use of pertussis toxin, a specific inhibitor of Gai-
protein signaling, dose dependently restored cellular adhesion in
CXCL12-expressing cells (Figure 1C). Reflecting our previous
studies in breast cancer carcinomas, CXCR4 surface expression
was unaltered between control and CXCL12-expressing cells
(Supplemental Data Figure S1) [23]. These data indicate that
CXCL12-mediated loss of adhesion requires activation of Gai-
protein coupled receptors and is not a function of homologous
chemokine receptor desensitization.
Tonic CXCL12 stimulation induces breakdown of focal
adhesions
With autocrine CXCL12 expression resulting in increased levels
of secreted proteins and decreased adhesion we focused on focal
adhesion proteins which are main mediators of cell-substrate
adhesion. Focal adhesions consist of several proteins including
Pyk2, paxillin, focal adhesion kinase (FAK), and p130Cas that link
the cellular cytoskeleton to the extracellular matrix through
transmembrane integrin proteins. Immunoblot analysis indicated
Figure 1. Autocrine CXCL12 decreases cell adhesion of
colorectal carcinoma cells. (A) RT-PCR characterization of CXCL12,
CXCR4 and CXCR7 mRNA expression in colorectal carcinoma cell lines.
MCF-7 cells and peripheral blood mononuclear cells (PBMC) were
analyzed as positive controls for CXCR7 or CXCR4 mRNA expression,
respectively. GAPDH expression served as a loading control. (B) HT29
cells cultured in complete medium exhibit decreased adhesion after 6-
days in culture (D0, D2, D4, D5, D6) compared to control (GFP) cells by
phase microscopy (10X). (C) Daily administration of the Gai-inhibitor
pertussis toxin (400 ng/ml or 800 ng/ml) restored adhesion in CXCL12-
expressing cells. * indicates statistically significant difference between
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levels of Pyk2, paxillin, FAK, and p130Cas (Figure 2A). We
determined that phosphorylation of paxillin, FAK, p130Cas, and
to a lesser extent Pyk2, decreased rapidly and preceded dimini-
shment in total cellular levels of those proteins in CXCL12-
expressing cells (Figure 2A). Control (GFP) cells maintained focal
adhesion protein activation and integrity. Together these data
mirror our prior work investigating FAK phosphorylation of
tyrosine residue 397 [13] and suggest CXCL12 expression has a
broad and significant impact on proteins within the focal adhesion
complex.
Given the relatively short half-life of CXCL12 [28] we sought to
test the hypothesis that cellular expression of CXCL12 mediates
distinct autocrine and paracrine functions relative to transient
endocrine stimulation of cells. A transwell co-culture approach was
used to physically separate CXCL12-expressing cells from control
(GFP) HT29 cells and both cellular adherence and focal adhesion
activation was ascertained. As shown in Figure 2B, CXCL12-null
HT29 cells were markedly less adherent when cultured in
proximity with cells continually producing the chemokine.
Fluorescence microscopy confirmed that the reduced adherence
of GFP control cells on inserts was not a function of chemotactic
emigration toward CXCL12 secreting cells (data not shown).
Consistent with data in Figure 2A, immunoblot analysis of cells
cultured on inserts indicated decreased FAK phosphorylation and
total protein in control HT29 cells co-cultured in proximity with
CXCL12-secreting cells (Figure 2C). Moreover, HT29 cells
expressing variable levels of CXCL12 (Hi and Med) demonstrated
decreasing levels of total FAK protein (Figure 2C) coincident with
diminished adherence (Figure 2D). The ability of CXCL12-null
HT29 cells to adhere to the filter was also dose-dependently
decreased when co-cultured with cells producing variable levels of
the chemokine (Figure 2D). Transient 24 hr stimulation with
exogenously added CXCL12 to mirror endocrine chemokine
gradients was unable to recapitulate the decreased adhesion
phenotype in CXCL12-null cells (data not shown). Immunofluo-
Figure 2. Constitutive CXCL12 stimulation induces a loss in adhesion through destabilization of focal adhesions. (A) HT29 cells
expressing CXCL12 or GFP were grown to confluency as an adherent monolayer and then serum-starved three days (D0–D3). Total cell lysates were
collected and immunoblot analysis conducted to examine both activation and presence of various focal adhesion proteins. GAPDH served as a
loading control. CXCL12 expression resulted in a loss of focal adhesion activation, indicated by diminished phosphorylation, and loss of total protein
levels. (B) CXCL12 or GFP HT29 cells were separately grown to confluency on filters or plastic and then co-cultured in serum-free medium. Adherent
cells were quantified by crystal violet staining after 3 or 6 days and compared to baseline adherence at day 0. Co-cultures are identified by fractions
with the numerator representing cells in the top-well insert and denominator representing cells in the bottom-well. CXCL12-expressing cells inducea
decrease in cellular adhesion in control cells. (C) Lysates from cells in the top-well after six days of co-culture were collected to examine FAK activation
and stability. Constitutive CXCL12 stimulation diminished active and total FAK levels whereas control (GFP/GFP) cells were unaffected. Data from
panels A-C are representative of three independent experiments. (D) Transwell co-cultures with HT29 cells expressing variable levels of CXCL12
resulted in a dose dependent decrease in adhesion. Values of top-well crystal violet staining shown are mean 6 SD from three independent
experiments completed in triplicate. * indicates statistically significant difference in panel D from GFP/GFP co-cultured cells (P#0.05). (E,F)
Immunofluorescence staining and overlay (yellow) of active phosphorylated paxillin (green) with total paxillin protein (red) demonstrated the
localization of focal adhesions in HT29 cells at day 0 (E) and day 3 (F) of adherent cultures. Size bar equals 20 mm.
doi:10.1371/journal.pone.0012895.g002
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intact and punctate staining consistent with focal adhesion
formation in both wild-type and CXCL12-expressing HT29 cells
in full growth medium (Figure 2E). Mirroring data in Figure 2A,
paxillin levels were markedly decreased in CXCL12-expressing
cells, compared to control, after 3-days in culture (Figure 2F).
Together these data describe a role for tonic CXCL12 expression
and production in regulating focal adhesion stability and cellular
adherence.
Autocrine CXCL12 expression sensitizes epithelial cells to
anoikis
Our previous studies have shown that IEC6 normal intestinal
epithelial cells express both CXCR4 and its ligand CXCL12 [14].
Additionally, our immunohistochemical analyses have determined
that CXCL12 expression to be maximal at the crypt apex [24].
These data suggest that CXCL12 could potentially be involved in
epithelial sheet turnover. To test that hypothesis, we first
determined that normal, non-transformed IEC6 cells exhibit
robust caspase activation and apoptosis during anchorage-
independent growth (Figure 3A–B). In agreement with those data
and reports of gut epithelium in vivo [1], HCT116 (Figure 3C–D)
and HT29 (Figure 3E–F) human colorectal carcinoma cells
engineered to stably express CXCL12 exhibited increased
activation of executioner caspases-3/7 compared to CXCL12-
deficient carcinoma cells. Propidium iodide staining confirmed
DNA degradation and increased apoptosis in those cells producing
CXCL12 relative to control cells (Figure 3B,D,F). Caspase-3/7
activation in CXCL12 cells was sensitive to the broad-spectrum
caspase-inhibitor zVAD, consistent with apoptosis (Figure 3A,C,E).
Maximal apoptotic cell death of non-adherent cultures was noted
at day four in carcinoma cells relative to 24 hrs in non-
transformed cells. These data suggest that CXCL12 expression
sensitizes colorectal carcinomas to anchorage-independent cell
death characteristic of the non-transformed epithelium.
CXCL12 utilizes intrinsic apoptotic machinery in anoikis
As both intrinsic and extrinsic apoptotic mechanisms have been
implicated in detachment-induced cell death [2], we next
investigated the apoptotic mechanism regulating anoikis sensitivity
in response to tonic CXCL12 production. As a first step, we
examined activity levels of the extrinsic apoptotic initiator,
Figure 3. Re-establishment of CXCL12 expression enhances anchorage-independent cell death. (A, B) Non-transformed rat IEC6
intestinal epithelial cells were cultured as a suspension on poly-HEMA [10 mg/ml]-coated dishes. Caspase-3/7 activity (A) was measured using a
luminescence-based assay. Execution of apoptosis was confirmed by propidium iodide staining (B) to display DNA degradation. Addition of zVAD
[10 mg/ml], a pan-caspase inhibitor, blocked caspase-3/7 activity. Stable HCT116 (C, D) and HT29 (E, F) human colorectal carcinomas expressing
CXCL12 or GFP (control) were plated on poly-HEMA. CXCL12 re-expression minimally altered baseline cell death at day-0 but markedly enhanced
non-adherent cell death over time indicated by heightened caspase-3/7 activity and DNA degradation relative to GFP control cells. Values in panels
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carcinoma cells secreting varying amounts of CXCL12 (Hi, Med,
Low) [24]. Immunoblot analysis indicated increased active,
cleaved caspase-9 levels solely in non-adherent CXCL12-express-
ing cells compared to active caspase-8, suggesting an intrinsic
apoptotic mechanism driving anoikis of those cells (Figure 4A).
Gliotoxin, a known inducer of apoptosis, confirmed equal and
functionally intact apoptotic machinery in GFP and CXCL12-
expressing cells (Figure 4A). Consistent with those data, initiator
and executioner caspase activities were measured by specific glo-
assays. HT29 (Figure 4B) and HCT116 (Figure 4C) cells
producing varying levels of CXCL12 demonstrated a dose-
dependent and preferential increase in caspase-9 activity relative
to caspase-8 after four days of adherent cell culture, consistent with
the activation of an intrinsic apoptotic mechanism.
Intrinsic apoptosis is largely governed by the balance of Bcl-2
family members that dictate cell fate [8]. Congruent with our
analysis of initiator caspase activity, we investigated the levels of
several Bcl-2 members in non-adherent HT29 cells expressing
CXCL12 to define which protein(s) were regulating apoptosis. As
Figure 4. Constitutive CXCL12 expression induces anoikis through an intrinsic apoptotic mechanism. (A) CXCL12 and GFP HT29 cells
were grown for 4-days as a suspension on poly-HEMA [10 mg/ml]-treated plates (Sus.) and whole cell lysates collected and compared to cells grown
as an adherent monolayer (Adh.). Active cleaved caspase-8, -3, -7, and -9 indicated the predominant activation of an intrinsic apoptotic pathway in
CXCL12 cells relative to control. Gliotoxin [2 mg/ml] confirmed intact apoptotic machinery in both cell lines. (B,C) Luminescence-based caspase
activity assays were used to examine levels of both initiator caspases-8 and -9 and executioner caspases-3/7 after 4-days on poly-HEMA. Clonal HT29
(B) and HCT116 (C) cell lines expressing variable levels of CXCL12 (Hi, Med, Low) indicated a dose dependent effect of caspase activity which was
inhibited with addition of zVAD. Values are mean 6 SD of 3 independent experiments completed in triplicate. (D) GFP and CXCL12 HT29 cells were
cultured on poly-HEMA-treated plates and lysates collected over time. Immunoblot analysis revealed a decrease in Mcl-1 and Bcl-2 levels and an
increase in Bim in CXCL12-expressing cells. Arrowhead indicates a lower molecular weight protein consistent with an Mcl-1 degradation product. (E)
HT29 cells expressing variable levels of CXCL12 exhibit increased Bim expression after a 4-day culture on poly-HEMA. (F) Immunoblot analysis of
adherent HT29 cells demonstrate the temporal loss of FAK activation precedes decreased Mcl-1 levels in CXCL12-expressing cells cultured as an
adherent monolayer on tissue culture plastic. Data are representative of three independent experiments. * indicates statistically significant differences
in caspase activity between GFP and CXCL12-expressing cells (P#0.05).
doi:10.1371/journal.pone.0012895.g004
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Mcl-1 and Bcl-2 expression coincident with the marked increase in
Bim protein levels in anoikis sensitive CXCL12- expressing cells.
Mcl-1 and Bcl-2 expression was sustained in anoikis-resistant
control cells cultured in suspension on poly-HEMA. Bcl-XL and
Bad protein levels were unchanged between adherent and non-
adherent CXCL12 and control cells. Cleaved PARP confirmed
increased apoptosis in cells producing the chemokine (Figure 4D).
Interestingly, decreased FAK activation and protein levels
preceded the alterations in Mcl-1 and Bim levels (Figure 4D).
Bim protein expression was markedly increased in three separate
clones of CXCL12 expressing cells, consistent with its key role in
anoikis-sensitivity and decreased metastatic potential in those cells
(Figure 4E). Analysis of adherent HT29 cells confirmed that loss of
FAK activation preceded decay in Mcl-1 protein levels (Figure 4F)
observed in cells in suspension (Figure 4D). Consistent with its key
role in anoikis, Bim was undetectable in these adherent culture
time points (data not shown), further supporting the notion that
loss of focal adhesions and decreased adherence precede Bim
upregulation. Together, these data indicate that persistent
CXCL12 stimulation induces anoikis by shifting the balance
between Bim and Mcl-1/Bcl-2 levels to activate caspase-9 and
intrinsic apoptosis.
CXCL12 induces cytochrome c release via Bak
upregulation
Bcl-2 family members regulate the ability of Bak and Bax to
permeabilize the mitochondrial outer membrane and initiate
cytochrome c release into the cytosol [7]. We next sought to
determine whether Bak or Bax expression was increased in anoikis
sensitive CXCL12-expressing cells. RT-PCR (Figure 5A) and
immunoblot (Figure 5B) analyses of HT29 cells revealed Bak
expression was markedly increased in adherent and non-adherent
carcinoma cells expressing CXCL12 relative to the transfection
control GFP cells. Contiguous with Bak upregulation, cytochrome
c release to the cytosol was observed solely in CXCL12-expressing
cells whereas control cells retained cytochrome c in the
mitochondria (Figure 5C). Immunoblot analysis of the resident
mitochondrial protein Complex IV confirmed efficient mitochon-
drial fractionation. Together these results suggest constitutive
CXCL12 production during anchorage-independent growth
induces anoikis via Bak upregulation resulting in subsequent
release of cytochrome c.
CXCL12 expression and adhesion are unaffected by Bim
repression
Having demonstrated Bim expression was upregulated in non-
adherent colorectal carcinoma cells expressing CXCL12, we next
examined whether RNAi-mediated repression of Bim would
reverse anoikis sensitivity in those cells. Using a lentiviral system,
we created wild-type and CXCL12 HCT116 cells stably
expressing an shRNA sequence that specifically silences extra-
long (EL), long (L) and short (S) Bim isoforms. As controls, stable
cell lines expressing a scramble shRNA or an empty vector (mock)
were utilized. Immunoblot (Figure 6A) and densitometry
(Figure 6B) analyses of non-adherent cultures confirmed the
75% knockdown efficiency of Bim protein levels in CXCL12-
expressing cells. Interestingly, Bim repression resulted in the
concomitant increase in Mcl-1 and Bcl-2 levels in CXCL12-
producing, but not wild-type, cells mirroring our results seen in
HT29 cells (Figure 4D). FAK levels were also unaltered by Bim
depletion (Figure 6A) and were consistently decreased in
CXCL12-expressing cells as noted in HT29 cells. Lentiviral
transduction with shRNA to Bim, scrambled transcript, or empty
(mock) vectors did not modulate ligand or receptor transcript
expression (Figure 6C) nor CXCL12 secretion (Figure 6D) in our
colonic carcinoma cell lines. Next, we determined that Bim
knockdown had little to no effect on cellular adherence in
CXCL12 or wild-type cells compared to untransduced (mock)
parental cells suggesting Bim is not regulating focal adhesions
(Figure 6E). These data suggest that CXCL12 inversely governs
Mcl-1 and Bcl-2 through the Bim regulator and that Bim
knockdown does not modulate the ability of those cells to adhere
suggesting focal adhesion signaling is working upstream of Bim.
Bim knockdown reverses anoikis sensitivity in
CXCL12-expressing cells
Bim-depleted cells were then examined to test the hypothesis
that Bim regulates anoikis sensitivity in colonic carcinoma cells
producing CXCL12. Previously our laboratory has shown that
CXCL12-expressing colorectal carcinoma cells are impaired in
both their ability to form foci on soft-agar and actively metastasize
[13]. As shown in Figure 7A, Bim depletion resulted in robust soft-
agar foci formation in CXCL12-expressing cells. In agreement
with our prior work, soft-agar foci formation was limited in
CXCL12 cells and unaffected by lentiviral transduction with
empty (mock) or scrambled shRNA (Figure 7A). Carcinoma foci
were of equal size in CXCL12-expressing cells depleted of Bim as
chemokine-deficient wild-type HCT116 cells (Figure 7B). Consis-
Figure 5. Bak expression is upregulated in non-adherent
colorectal carcinoma cells expressing CXCL12. (A) HT29 stable
cell lines expressing varying levels of CXCL12 were plated for 4-days on
poly-HEMA [10 mg/ml]. RT-PCR analysis shows an increase in Bak but
not Bax transcript levels in CXCL12-expressing cells in relation to control
GFP cells. (B) Immunoblot analysis confirms increased Bak protein levels
in CXCL12-expressing cells cultured in suspension for either 2, 4 or 6
days (D2, D4, D6) compared to control. (C) Mitochondrial fractionation
and immunoblot analysis of GFP and CXCL12 cells after four days of
anchorage-independent growth indicated a release of cytochrome c
into the cytosol in CXCL12-expressing cells. Complex IV, a resident
mitochondrial protein, confirmed efficient fractionation and GAPDH
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expressing cells significantly decreased executioner caspase-3/7
activity (Figure 7C) and DNA degradation (Figure 7D) in HCT116
cells cultured in suspension. Together these data suggest that
constitutive CXCL12 expression and production inhibits tumor
formation by sensitizing colorectal carcinoma cells to anoikis via
upregulation of the Bim regulator.
Bim knockdown enhances metastatic potential of
CXCL12-expressing cells
To test that notion, our previously established HCT116
carcinoma cells expressing firefly luciferase and CXCL12
(CXCL12-Luc) or GFP (GFP-Luc) as control [13] were trans-
duced with lentivirus to establish Bim knockdown cells. HCT-Luc
cells transduced with empty vector (mock) or scrambled shRNA
served as controls. Tumor cells were implanted in the cecal wall of
immunodeficient SCID mice and tumor progression monitored
over time using bioluminescence imaging. Consistent with our
previous reports, GFP-Luc cells exhibited strong tumor growth
with each of the animals developing liver metastases irrespective of
Bim depletion (Figure 8A,B). CXCL12-Luc cells, which we have
shown to be poorly metastatic, were unaffected by lentiviral
transduction of mock or scramble shRNA viral particles with only
one of eight animals developing a hepatic metastases. In parallel
with our soft-agar experiments, knockdown of Bim in CXCL12-
Luc cells partially restored metastatic potential of these cells,
resulting in half of the mice developing hepatic tumors (Figure 8A
and C). Mirroring our previous findings (Figure 8D), net tumor
burden was slightly decreased, but not statistically different, over
time in CXCL12-Luc mice compared to GFP-Luc controls and
was unaffected by Bim depletion [13]. These data support the
model that increased Bim expression in CXCL12-producing cells
plays key roles in decreased metastatic potential relative to primary
tumor growth of those colonic carcinoma cells.
Discussion
Induction of anoikis provides a key regulatory mechanism for
normal intestinal epithelial homeostasis and offers a potent
limitation to tumor dissemination. Invasion and metastasis are
responsible for 90% of cancer-associated mortalities with some
cases of the tumor cells being more enumerated in secondary
tissues than the primary growth site.[2] With resistance to anoikis
being a hallmark of metastatic cancers, it is critical to understand
mechanisms governing this process. In contrast to the current
model that extracellular mediators primarily induce extrinsic
apoptosis or repress anoikis sensitivity, our studies suggest that
CXCL12 represents a novel secreted mediator of anoikis.
Although classically characterized as directors of cellular
migration, chemokines have since have been shown to be involved
in a broad range of cellular processes [15,16,19]. Recently, the
homeostatic chemokine CXCL12 has been shown to be an
essential mediator of cancer metastasis, with our laboratory
demonstrating that silencing of endogenous CXCL12 expression
establishes a pro-metastatic phenotype [20,23,24]. These studies
suggest there are stark differences in cellular outcomes with
endogenous and exogenous CXCL12 signaling. In particular,
roles for CXCL12 in cell death have been controversial, with
studies describing it either as an inducer or a repressor of apoptosis
[13,16,25]. Kochetkova and colleagues showed that transient
CXCL12 stimulation increased tumor metastasis by inhibiting
anoikis through induction of Bmf and Bcl-XL anti-apoptotic
Figure 6. Bim depletion restores anti-apoptotic protein expression independent of changes in cellular adherence. (A) HCT116 cells
were transduced by lentiviral particles encoding shRNA to create stable knockdown cell lines. Efficient knockdown of Bim levels after four days of
non-adherent growth on poly-HEMA was confirmed by immunoblot analysis. Increased levels of Bcl-2 and Mcl-1 corresponded with Bim knockdown
in CXCL12-expressing cells. Empty virus lacking shRNA and virus expressing a scrambled shRNA served as controls. (B) Densitometry analysis from 3
separate immunoblot analyses revealed a 75% knockdown of Bim protein levels in CXCL12 cells stably expressing Bim shRNA. (C) RT-PCR analysis
confirmed CXCL12, CXCR4, and CXCR7 transcript levels were unchanged in Bim knockdown cells. (D) Enzyme-linked immunosorbent assay confirmed
minimal alteration in CXCL12 secretion following lentiviral transduction. (E) HCT116 stable cell lines were grown to confluency and then serum-
starved 6-days to determine if Bim depletion affected cellular adhesion. Crystal violet staining indicated adhesion was not significantly different
between untransduced and RNAi-expressing cell lines. Values in D and E are mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0012895.g006
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previously shown that re-establishment of endogenous CXCL12
expression inhibits metastasis and sensitizes colorectal carcinoma
cells to anoikis [13]. Data herein delineate the molecular process
by which CXCL12 re-expression regulates Bim and Mcl-1 to
initiate anoikis in colorectal cancers. The dichotomy in CXCL12
functions in anoikis potentially reflects a difference between
transient and constitutive chemokine expression, as tonic chemo-
kine production elicited anoikis in distinct colonic carcinoma cell
lines. Alternatively, as suggested by our prior report of increased
proliferation in CXCL12-expressing human breast cancer cells
[23], differential sensitivity to anoikis may point toward carcino-
ma-specific roles for CXCL12 in modulating carcinogenesis.
Mechanisms regulating anoikis in normal epithelial turnover
and transformed colorectal carcinomas remains unclear. Herein,
we show re-establishment of CXCL12 expression is a novel
inducer of Bim and Bak in colorectal carcinoma cells and sensitizes
these cells to anoikis. In normal intestinal epithelium expression of
CXCL12 parallels Bak along the crypt-villus axis with maximal
protein observed at the crypt apex [24,29]. Recently, Duckworth
and colleagues showed increased crypt hyperplasia and suppressed
epithelial cell apoptosis in Bak-null mice signifying a critical role
for Bak in normal intestinal epithelial turnover [30]. It is tempting
to postulate that CXCL12 is a novel extracellular regulator of Bak
and that this signaling axis is important in normal epithelial
turnover. Coinciding with our data, decreased Bak and Bim
expression are correlated with diminished disease prognosis
suggesting downregulation of these proteins are critical for
apoptotic resistance [31,32]. Conversely, upregulation of Mcl-1
in colorectal carcinomas results in diminished efficacy of
chemotherapy treatments such as 5-fluorouracil [33] and has
been shown to mediate anoikis resistance in other cancer types
[9,10,34]. Therefore, therapies aimed to restore expression levels
of these pro-apoptotic Bcl-2 family members could improve
patient prognosis. Our data suggest re-establishment of CXCL12
expression in colorectal carcinomas potentially serves as a target to
sensitize these cells to chemotherapies while limiting metastatic
progression by modulating levels of Bcl-2 family members.
Successful metastasis requires a degree of active focal adhesions
in the context of an anoikis-resistant anti-apoptotic signaling
mechanism. Our data show constitutive CXCL12 stimulation
results in a loss of cellular adherence via downregulation of focal
adhesions. Further, our data indicate that Bim depletion had little
effect on formation or stability of focal adhesion proteins, with
Figure 7. Bim knockdown rescued anchorage-independent growth in CXCL12-expressing colorectal carcinoma cells. (A, B) HCT116
stable cell lines were grown for two weeks on soft-agar to examine anchorage-independent cell growth. Foci formation was examined using bright
field microscopy under 40X and 200X objectives. Bim knockdown rescued anoikis resistance in CXCL12-expressing colorectal carcinomas to
equivalent levels as GFP controls. (C) Cells were cultured 4-days as a suspension on poly-HEMA treated plates and caspase-3/7 activity measured.
Depletion of Bim in CXCL12 cells decreased caspase-3/7 activity to GFP control levels. (D) Sub-G1 populations indicating DNA degradation were
diminished with Bim knockdown in CXCL12-expressing cells but not in control cells. Values are mean 6 SD of three independent experiments
completed in triplicate. * indicates statistically significant between CXCL12 untransduced and transduced cells (P#0.05).
doi:10.1371/journal.pone.0012895.g007
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competent CXCL12 cells. Moreover, our analyses indicate focal
adhesionproteinlossofactivityanddegradationtemporallyprecedes
alterations in Mcl-1 and Bim expression levels, which themselves
regulate activation of the caspase family members (Figure 9). These
data mirror a prior report showing that epithelial anoikis reflects
focal adhesion complex-dependent disruption in the balance
between pro-apoptotic and anti-apoptotic Bcl-2 family members
[35]. Studies with knockdown cells revealed a key role for Bim in the
survivability of metastatic tumor cells expressing CXCL12 in an in
vivo orthotopic xenograft model. The lack of an intact focal adhesion
complex in those cells likely provided an additional barrier to
metastasis, preventing a complete reversal in metastasis of
chemokine-producing carcinoma cells. We hypothesize that main-
taining focal adhesion protein expression, which is absent in
CXCL12 cells regardless of Bim levels, is critical for further enabling
metastasis of colorectal carcinomas expressing the chemokine.
Recently CXCL12 has been shown to bind the chemokine
receptor CXCR7 [26]. In agreement with CXCR4, upregulation of
CXCR7 enhances the metastatic potential of several carcinomas
[26]. Interestingly, CXCR7 and CXCR4 appear to have divergent
cellular functions with CXCR7 influencing cellular adhesion and
CXCR4 directing migration, suggesting differential chemokine
signaling mechanisms [36,37]. However, given the unclear signaling
mechanisms whereby CXCR7 mediates those effects, it is difficult to
rigorously define the role for that receptor in apoptosis and
tumorigenesis. Future studies will examine the role of CXCR4 and
CXCR7 in CXCL12-mediated anoikis to determine if loss of
adhesion and anchorage-independent cell death are differentially
regulated through those receptors. It is also of interest to examine if
transient and constitutive CXCL12 stimulation of either CXCR4 or
CXCR7 elicits distinct cellular outcomes. Similarly, it is possible that
transient ligand exposure results in homologous receptor desensiti-
zation of both CXCR4 and CXCR7, while those receptors are more
resilient to more sustained receptor activation. The impact of
sustainedCXCR4andCXCR7activationonthedesensitizationand
recycling of those receptors has yet to be explored, but may provide
novel avenues with which we can specifically activate or de-activate
chemokine receptors in human disease. We propose that constitutive
CXCL12 stimulation more accurately represents the environment of
the intestinalepitheliumwherecellularmigrationfromthecryptbase
to the villus tip occurs along gradients of CXCL12.
Together, these data extend our understanding of CXCL12-
mediated blockade of metastasis by defining mechanistically the
signaling aperture utilized in anoikis. Our data indicate an intrinsic
apoptotic pathway executing anoikis as evidenced by preferential
caspase-9activityandcleavage.Thesestudiesalsoidentifypreviously
uncharacterized interactions between CXCL12 and Bcl-2 family
members in colorectal carcinomas through upregulation of Bim and
downregulation of Mcl-1. Repression of Bim protein levels by RNAi
rescued anoikis resistance in CXCL12-expressing cells describing
Bim as a critical physiological step for colorectal carcinoma
anchorage-independent survival and tumor metastasis. Together,
these data suggest constitutive CXCL12 expression is a novel
extracellular regulator of anoikis by inducing Bim-mediated intrinsic
apoptotic pathway and inhibiting metastasis.
Figure 8. Bim knockdown partially restores metastasis of CXCL12-expressing colorectal carcinoma cells. HCT116 cells expressing either
GFP and Firefly luciferase (GFP-Luc) or CXCL12 and Firefly luciferase (CXCL12-Luc) were orthotopically xenografted to the cecal wall of SCID mice.
Tumor formation and hepatic metastases was monitored in real-time using biophotonic imaging. (A) Five-weeks after engraftment, GFP-Luc
carcinoma cells consistently metastasized to the liver, as measured ex vivo. CXCL12-Luc cells were markedly less metastatic as shown in excised liver
from mice engrafted with CXCL12-expressing cells transduced with empty lentiviral particles (mock) or particles encoding non-specific shRNA
sequences (shScram). Bim depleted CXCL12 cells successfully metastasized to the liver. (B) Equivalent levels of HCT116 GFP-Luc and CXCL12-Luc cells
were engrafted to the cecal wall as day 0 (top panels). Control cells formed larger tumors after 4-weeks growth (lower panels). Data in A and B are
representative of 3–4 animals per group. (C) Liver metastases were enumerated using biophotonic imaging and demonstrated robust hepatic tumor
levels in GFP-Luc (open symbols) cells compared to CXCL12-Luc (filled symbols). Data in C presented as radiance (RLU) normalized to background
luminescence. (D) Overall tumor burden was unaffected by Bim depletion and was diminished, but not statistically decreased, over the 4-week (W0–
W4) time-course in CXCL12-Luc cells (filled symbols) compared to GFP-Luc (open symbols) control cells. Data in D presented as radiance (RLU)
normalized to initial (W0) values immediately after implantation.
doi:10.1371/journal.pone.0012895.g008
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Cell lines, antibodies and reagents
HT29 (HTB-38) and HCT116 (CCL-247) human colorectal
carcinoma cells and IEC6 (CRL-1592) normal rat intestinal
epithelial cell lines were purchased from (ATCC Rockville, MD,
USA) and maintained as previously described [14,24]. HT29 and
HCT116 cells stably expressing either GFP or varying levels of
CXCL12 were previously established and described [24].
Antibodies specific for Bax, Bak, Mcl-1, Bim, phospho-Bad, total
Bad, Puma, Bcl-2, Bcl-XL, cleaved poly-ADP ribose polymerase
(PARP), cleaved caspase-3, cleaved caspase-9, cleaved caspase-8,
and cleaved caspase-7 were from (Cell Signaling, Danvers, MA,
USA). Polyclonal donkey anti-rabbit horseradish peroxidase
(HRP)-conjugated secondary antibody (Amersham, Piscataway,
New Jersey, USA) and SuperSignal West Pico Chemiluminescent
Substrate (Pierce, Rockford, IL, USA) were used for visualization.
Antibodies for monitoring focal adhesion proteins were: total
FAK, phospho-FAK (Y397), total paxillin, total p130Cas (Cell
Signaling), and phospho-paxillin (Y118), phospho-p130Cas
(Y410), total-Pyk2, phospho-Pyk2 (Y402) and phospho-FAK
(Y577/Y578) from (BD Biosciences, San Jose, CA, USA). Pertussis
toxin was used for inhibition of Gai dependent G-protein coupled
receptor signaling (EMD Calbiochem, San Diego, CA, USA).
Reverse Transcriptase Polymerase Chain Reaction
HCT116 cells (2610
6) were plated on poly-hydroxyethylmetha-
crylate (poly-HEMA) [10 mg/ml] (Sigma, St. Louis, MO, USA) in
serum-free medium for four days. Cells were then collected,
washed in PBS, and RNA was isolated using RNAeasy Kit
(Qiagen, Valencia, CA, USA). RNA (2 mg) was converted into
cDNA using random priming and Superscript-II reverse tran-
scriptase in a 40 ml volume. Bak and Bax mRNA expression was
amplified using 35 cycles of 94uC for 30 sec, 60uC for 30 sec, and
72uC for 30 sec. CXCL12, CXCR4 and CXCR7 expression were
amplified using 33 cycles of 94uC for 30 sec, 60uC for 30 sec, and
72uC for 30 sec. Analysis of GAPDH expression was used to assess
equality in cDNA levels between samples.
Receptor surface-expression
Confluent HT29 cells (,1610
6 cells) were detached with
20 mM EDTA in PBS, fixed 10 min at 4uC in 2% (w/v)
paraformaldehyde in PBS, and subsequently incubated 90 min at
4uC with 10 mg/ml of murine monoclonal antibodies to CXCR4
(clone 12G5, R&D Systems, Minneapolis, MN, USA) or a mouse
isotype matched control antibody as a control. Rabbit polyclonal
antibody was used to detect CXCR7 (Abcam, Cambridge, MA,
USA). Receptor staining was visualized by incubation with R-
phycoerythrin labeled goat anti-mouse IgG (Southern Biotechnol-
ogy Associates Inc., Birmingham, AL, USA) or AlexaFluor-488
labeled donkey anti-rabbit antibodies. Antibodies were optimally
diluted in PBS, 1.0% (w/v) BSA and 1.0% (v/v) goat or donkey
serum. Cells were analyzed by flow cytometry (Millipore, Billerica,
MA, USA) and histograms made using FlowJo7.6 software (BD
Laboratories, Sunnyvale, CA, USA).
Immunoblot analysis
HT29 or HCT116 cells were plated to confluence in 6-well
dishes and then serum-starved for varying times. Cells were
solubilized and total cell lysate prepared as previously described
[14]. Proteins were size separated using reducing SDS-PAGE,
electrotransferred to PVDF membranes and visualized with
appropriate HRP-conjugated secondary antibodies and Super-
Signal West Pico Chemiluminescence substrate (Pierce).
Propidium iodide staining
HT29 or HCT116 cells (4610
6) were cultured as a suspension
by plating to poly-HEMA-coated 10 cm dishes in serum-free
medium. After four days, cells were collected and washed in PBS.
Cells were ethanol fixed and stained with 50 mg/ml propidium
iodide (EMD Calbiochem) and 10 mg/ml RNAse A (Promega).
Figure 9. Schematic model of CXCL12-mediated anoikis in colorectal carcinoma cells. Cell culture in the presence of increasing levels of
secreted CXCL12 in autologously expressing colon carcinoma cell lines reveals a temporal loss of focal adhesion proteins and increased Bim
expression leading to increased anoikis and decreased metastatic potential. Initially, adherent cells expressing CXCL12 maintain expression and
activation of focal adhesion proteins (FAK, Pyk, p130Cas, and paxillin) along with high levels of pro-survival Bcl-2 family members (Mcl-1 and Bcl-2).
Prolonged production of CXCL12 leads to decreased focal adhesion activation and impaired cellular adhesion. Subsequently, levels of pro-survival
Bcl-2 proteins decrease with the concomitant increase in pro-apoptotic Bim and Bak proteins. Changing the balance in Bcl-2 family protein expression
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populations indicative of DNA fragmentation.
Caspase activation assay
Cells were plated (4610
6) in serum-free medium on poly-
HEMA-coated plates. Cells were collected at various time points,
mixed at a 1:1 volumetric ratio with glo reagent (Promega,
Madison, WI, USA) and incubated at room temperature for
30 min in the dark. Caspase-3/7, -8, and -9 activation was
measured using specific caspase glo reagents and quantified as
luminescence units using a spectrophotometer (Victor Wallac,
Turku, Finland).
Mitochondrial fractionation and cytochrome c release
Cells were grown until confluent on 10 cm dishes and then
serum-starved for four days. Total cells were collected, centri-
fuged, and washed twice in PBS. Using the MitoIso2 kit (Sigma),
cells were resuspended in 1 ml of 1x isotonic extraction buffer
with protease inhibitor cocktail (1:100) and incubated on ice for
15 min. Cells were placed in a Dounce homogenizer and lysed.
Homogenate was collected and centrifuged at 6006g for 10 min
at 4uC. Supernatant was transferred to a fresh tube and
centrifuged at 11,0006g for 10 min at 4uC. The cytosolic and
mitochondrial fractions were separately solubilized in 200 mll y s i s
solution supplied by the manufacturer (Sigma). Cytochrome c
release into the cytosolic fraction was analyzed by immunoblot
and complex IV confirmed efficient mitochondrial protein
isolation.
shRNA lentivirus construction and transduction
Bim shRNA was generated using the Lentilox3.7 system
(Addgene, Cambridge, MA, USA). The sequences for Bim shRNA
oligos were as follows: 59-tGGTTATCTTACG ACTGTTAttcaa-
gagaTAAC AGTCGTAAGATAACCtttttggaaac-39 and 59-
tcgagtt tccaaaaaGGTTATCTTACGACTGT TAtctcttgaaTAA-
CAGTCGTAAGATAACCa-39. Oligonucleotides were annealed
together and cloned into HpaI/XhoI digested pLL3.7 GFP or
pLL3.7 puromycin expression vectors. Plasmid orientation was
verified by PCR and DNA sequencing.
LL3.7 empty, scramble, or Bim shRNA vectors were transfected
along with accessory plasmids pVSVG, pREV, and pRRE into
HEK293T cells using Mirus-293 transfection reagent. Medium
was replaced after 24 hrs and conditioned medium containing
viral particles was collected 48 hrs later. Viral particle supernatant
was filtered through a 0.45 mm filter. HCT116 cells were
transduced with lentiviral particles in the presence of polybrene
[10 mg/ml] (Sigma) for 24 hrs. Medium was replaced and eGFP
expression monitored by flow cytometry 48 hrs later or cells
expressing the insert were selected with 5 mg/ml puromycin.
Knockdown of Bim was confirmed by immunoblot analysis.
Soft-agar foci formation assay
HCT116 GFP and CXCL12 stable cell lines (1610
5) expressing
Bim or scramble shRNAs were plated to 12-well dishes on a 1.0 ml
layer of 0.7% (w/v) bacto-agar (BD Bioscience) reconstituted in
serum-containing medium. Cells were then covered with 1.0 ml of
0.35% (w/v) warm agar in serum-containing medium. Cells were
cultured for two weeks and cellular foci were photographed and
foci number and area determined by an investigator blinded to the
status of the samples using Metamorph software. Ten represen-
tative images from each group were used to quantify foci area from
three separate experiments.
Adherence assay
HCT116 GFP and CXCL12 Bim shRNA or scramble control
cells were grown to confluency in a 12-well dish and then serum
starved four days. Cells were stained with crystal violet and
solubilized in 2% (v/v) SDS. Absorbance (595 nm) was quantified
using spectrophotometer (Victor Wallac) to determine levels of cell
adherence after serum deprivation.
Immunofluorescence Microscopy
Wild-type or CXCL12-expressing HT29 cells were grown to
confluency on coverslips in 6-well dishes. Cells were washed and
fixed with 2% (w/v) paraformaldehyde and permeabilized with
0.03% (v/v) Triton X-100. Coverslips were blocked with 1% (w/v)
BSA at room temperature for 1 hr and then incubated room
temperature for 2 hrs in primary antibody or isotype control
immunoglobulins. Cells were washed and incubated 1 hr at room
temperature with the appropriate secondary antibody, and co-
stained with 49,6-diamindino-2-phenylindole (Molecular Probes,
Invitrogen) to visualize nuclei. Images were obtained using a
fluorescence microscope at 600X magnification.
Mouse bioluminescence imaging
In accordance with protocols approved by the Medical College
of Wisconsin Institutional Animal Care and Use Committee,
metastatic HCT-Luc cells (2610
6) were suspended in 50 ml sterile
PBS were implanted to the subserosal layer of the cecum in eight-
week-old male immunodeficient SCID (cr-Prdkc
scid, Charles
Rivers, Wilmington, MA) mice following a midline laparotomy.
Tumor formation and metastasis was compared to HCT-Luc-
CXCL12 (2610
6) cells. Mice were imaged immediately after
implantation and then weekly by bioluminescence imaging
(Lumina IVIS-100 In Vivo Imaging System, Xenogen Corp,
Alameda, CA, USA). To visualize luciferase-expressing carcinoma
cells, mice received an intraperitoneal injection of D-luciferin and
anesthetized with isoflourane using the XGI-8 gas anesthesia
system (Xenogen). Mice were imaged for 30 seconds with medium
binning and an f-stop of 1 and Regions of Interest defined as
radiance (photons/second/cm2/steradian) and presented as
radiant luminescence units according to the manufacturer’s
calibration (Xenogen).
Statistical Analyses
Data were analyzed using Student’s unpaired t-test using
SigmaPlot (Systat Software, Inc., San Jose, CA, USA). A P-value
#0.05 was considered statistically significant.
Supporting Information
Figure S1 CXCR4 and CXCR7 surface receptor localization is
indistinguishable between CXCL12-expressing and chemokine
null colon carcinoma cells. Surface localization was determined
using flow cytometry. Upper panels. CXCR4 (A) and CXCR7 (B)
cell surface levels in wild-type (WT) HT29 cells. Mean
fluorescence intensity of CXCR4 (58.062.3) and CXCR7
(4.060.4). Lower panels. CXCR4 (C) and CXCR7 (D) membrane
levels in CXCL12-expressing HT29 cells. Mean fluorescence
intensity of CXCR4 (57.961.8) and CXCR7 (4.060.3). Values
are the mean6SEM n=3. Shaded areas represent unstained
samples. Histogram data are representative of three independent
experiments.
Found at: doi:10.1371/journal.pone.0012895.s001 (4.15 MB
TIF)
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